Flinders Investment Partners on ‘Groundbreaking technology, market opportunity and compelling partnerships':  Australian Financial Review‘s latest Techninvest edition: Read More »
Further validation of XV Technology application to COPD conditions, with results communicated to the global clinical and medical research communities by respected Johns Hopkins experts. Read More »
US advocacy organisation, the Physician-Patient Alliance for Health & Safety (PPAHS) has published a Position Paper recognising the need for improved technologies and procedures to measure lung dynamics and function during pandemics. Read More »
A second clinical trial validating the clinical application of 4DMedical’s XV Technology has commenced at Johns Hopkins University in Baltimore, one the world’s most renowned centres of research translation.   Read more about our comprehensive program of clinical trials.   Read More »
The 4DMedical community reflects upon the life and achievements of Jeff Goldstein, President and Founding Member, Lung Transplant Foundation, and a respected and valued partner in seeking to improve the lives of those afflicted with lung diseases. Jeff fulfilled both executive and board responsibilities within... Read More »
The influential and respected U.S. National Institutes of Health (NIH) has validated the multiple capabilities of 4DMedical's Permetium pre-clinical scanner, enabling a $600,000 commercial purchase by the University of Michigan.  In a comprehensive funding submission to the NIH, Michigan recognised Permetium as “the only commercially available... Read More »